NASDAQ · DBVT
Healthcare · Biotechnology
$10.11
Up+$1.06 (+11.71%)
Updated Nov 4, 2026, 4:02 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DBVT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
DBVT closed at $10.11 after 21 trading sessions, up 1.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $9.34 | $10.28 | $9.34 | $10.11 | 325.95K |
| Nov 2, 2026 | $9.53 | $9.61 | $8.93 | $9.05 | 207.36K |
| Oct 30, 2026 | $9.96 | $10.13 | $9.33 | $9.49 | 410.57K |
| Oct 29, 2026 | $9.35 | $10.75 | $9.34 | $10.29 | 1.03M |
| Oct 28, 2026 | $10.06 | $10.86 | $10.03 | $10.65 | 225.81K |
| Oct 27, 2026 | $10.00 | $10.49 | $9.92 | $10.125 | 641.36K |
| Oct 26, 2026 | $10.11 | $10.14 | $9.89 | $9.98 | 214.83K |
| Oct 23, 2026 | $9.68 | $9.78 | $9.45 | $9.75 | 258.34K |
| Oct 22, 2026 | $9.57 | $9.84 | $9.52 | $9.68 | 121.59K |
| Oct 21, 2026 | $9.53 | $9.9185 | $9.53 | $9.62 | 1.41M |
| Oct 20, 2026 | $8.95 | $9.625 | $8.89 | $9.48 | 210.57K |
| Oct 19, 2026 | $8.81 | $9.045 | $8.81 | $8.97 | 269.94K |
| Oct 16, 2026 | $9.02 | $9.13 | $8.63 | $9.05 | 592.92K |
| Oct 15, 2026 | $8.87 | $9.205 | $8.85 | $9.11 | 432.28K |
| Oct 14, 2026 | $9.09 | $9.115 | $8.86 | $8.87 | 351.2K |
| Oct 13, 2026 | $9.47 | $9.50 | $8.90 | $9.03 | 344.1K |
| Oct 12, 2026 | $9.63 | $9.72 | $9.39 | $9.55 | 311.79K |
| Oct 9, 2026 | $9.62 | $9.86 | $9.43 | $9.80 | 324.06K |
| Oct 8, 2026 | $9.74 | $9.84 | $9.36 | $9.55 | 603.27K |
| Oct 7, 2026 | $9.74 | $10.05 | $9.64 | $9.77 | 535.28K |
| Oct 6, 2026 | $10.64 | $10.66 | $9.82 | $9.98 | 558.01K |
The latest Smart Investors Daily articles mentioning DBVT.
Company
Market Activity
Research & News
DBVT research
Company profile and research snapshot.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2024 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Jun 16, 2024 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Mar 14, 2024 | SOCIETE GENERALE | Buy | — |
| Mar 13, 2024 | SOCIETE GENERALE | Buy | — |
| Dec 19, 2023 | PORTZAMPARC BNP PARIBAS | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
DBV Technologies (NASDAQ:DBVT) said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a potential commercial launch and addressing manufacturing readiness at its contr
Yahoo · Oct 28, 2026
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review Accelerated Commercial Readiness towards the launch of the VIASKIN® Peanut Patch in children aged 4-7 years in the US, if approvedReported cash and cash equivalents of $165.7 million as of September 30, 2026, funding into third quarter of
Yahoo · Oct 27, 2026
Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Wednesday, October 28th, at 5:00 p.m. ET to review its third quarter 2026 financial
Yahoo · Oct 16, 2026
European equities traded in the US as American depositary receipts were tracking higher late Friday
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DBVT.
